Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911042 | 1.00 | CYP1A2 (0.42) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL96802 | 0.97 | — | — | |
| SCHEMBL5218136 | 0.92 | — | — | |
| SCHEMBL98082 | 0.86 | — | — | |
| SCHEMBL8390897 | 0.85 | CYP1A2 (0.50) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL99022 | 0.85 | CYP1A2 (0.50) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 | |
| SCHEMBL7350448 | 0.83 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL97094 | 0.83 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL1335898 | 0.83 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL8075929 | 0.83 | ALDH1A1 (0.32) | CYP1A2HPGDEPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-4267340-A | BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | claimed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | claimed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | claimed |
| EP-3219717-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9597327-B2 | Synthesis of (R)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals., Inc. | 2015-10-15 | — | — | US | disclosed |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8343992-B2 | Synthesis of R-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-4084049-A | CEPHALOSPORIN ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-04-11 | — | — | US | disclosed |
| US-4071527-A | Certain benzothiazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-01-31 | — | — | US | disclosed |
| US-4036847-A | ANTIBACTERIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-07-19 | — | — | US | disclosed |
| US-4035405-A | Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | disclosed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | disclosed |
| US-3984397-A | CYCLIZATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
| US-3954732-A | BACTERICIDAL PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323286-A1 | SYNTHESIS OF R-N-METHYLNALTREXONE | OPRM1, OPRK1, OPRL1 | CYP1A2 338/4885SIGMAR1 163/4885HPGD 611/4885 |
| US-20170143700-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | CYP1A2 363/4885SIGMAR1 120/4885HPGD 707/4885 |
| US-20150057303-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | CYP1A2 363/4885SIGMAR1 120/4885HPGD 707/4885 |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | CYP1A2 363/4885SIGMAR1 120/4885HPGD 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.